Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A worldwide, multicenter, double-blind, parallel study to evaluate the tolerability of MK-0524A [niacin/laropiprant] versus niacin extended-release

Next Previous
Trial Profile

A worldwide, multicenter, double-blind, parallel study to evaluate the tolerability of MK-0524A [niacin/laropiprant] versus niacin extended-release

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 06 May 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Niacin/laropiprant (Primary) ; Niacin
  • Indications Lipid metabolism disorders
  • Focus Adverse reactions; Registrational
  • Sponsors Merck & Co; Merck Sharp & Dohme Corp.

Most Recent Events

  • 01 Apr 2008 Results were presented at the 57th Annual meeting of the American College of Cardiology.
  • 07 Mar 2008 Status changed from in progress to completed as reported by ClinicalTrials.gov.
  • 15 Nov 2006 Status change

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top